Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life

Hepatic Encephalopathy Clinical Trial

— MHE  

Official title:

Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01008293
• Other study ID #: MHE-VSL3-YKJ_AIIMS_ver1
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: November 4, 2009
• Last updated: June 3, 2013
• Start date: October 2009
• Est. completion date: October 2012

Study information

• Verified date: June 2013
• Source: CD Pharma India Pvt. Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: India: Drugs Controller General of IndiaIndia: Indian Council of Medical Research
• Study type: Interventional

Clinical Trial Summary

This study is a randomized, open, parallel group, active comparator, single center trial. Objectives of the study are hereby given below:

• To study the health related quality of life (HRQOL) in patients with chronic liver disease.

• To assess the prevalence of minimal hepatic encephalopathy (MHE) in patients with chronic liver disease and assessment of HRQOL in patients with MHE.

• To compare the effect of probiotics and lactulose in the treatment of MHE

• To assess the effect of probiotics and lactulose on the HRQOL in patients with MHE.

Description:

The study design would comprise of two parts

1. Part I: Cross sectional study: This part would comprise of the assessment of HRQOL in patients with CLD

1. All the consecutive patients diagnosed as CLD would be enrolled in the study. All these patients would be enrolled from the liver clinics of the department of gastroenterology and those admitted in the gastroenterology ward at AIIMS.

2. Alcohol would be considered to be the cause of CLD, if the patient regularly consumed ≥80g/d of alcohol for five years

3. The staging of cirrhosis would be done according to the Child Pugh classification:

A, B and C

4. The causes of CLD would be divided into:- viral hepatitis, alcohol, viral hepatitis combining with alcohol and miscellaneous causes

2. Part II: Prospective randomized controlled trial: In this part the outcome of lactulose and probiotic therapy in the treatment of MHE and its effect on the HRQOL will be compared.

1. All the consecutive patients with CLD without overt encephalopathy would be screened for MHE.

2. All these patients would be enrolled from the liver clinics and the gastroenterology ward, AIIMS.

3. The diagnosis of MHE would be based on abnormal psychometric tests (NCT-A and NCT-B or FCT-A and FCT-B) and /or abnormal P300 auditory event related potentials.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: October 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 15 Years to 80 Years

Eligibility

Inclusion Criteria:

• All the patients with Chronic Liver Disease or Minimal Hepatic Encephalopathy (without overt hepatic encephalopathy) aged between 15 to 80 years of both the genders would be enrolled consecutively.

Exclusion Criteria:

• Patients with overt hepatic encephalopathy

• Active medical co-morbidities like CHD, chronic respiratory disease, chronic renal disease, malignancies, diabetes etc

• Malignancy

• History of taking lactulose or probiotics or antibiotics, in the past 6 weeks

• Presence of other neurological or psychiatric disorder

• Patients who underwent shunt surgery for portal hypertension

• History of taking medicines likely to interfere with psychometric performance

• History of GI hemorrhage or spontaneous bacterial peritonitis during the past 6 weeks

• Presence of mature cataracts and diabetic retinopathy

• Refused to participate in the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Brain Diseases
• Chronic Liver Disease
• Hepatic Encephalopathy
• Liver Diseases

Intervention

Drug:
• VSL#3
VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
• Lactulose
30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.

Locations

Country	Name	City	State
India	Dept. of Gastroenterology and H.N.U., All India Institute of Medical Sciences	New Delhi	Delhi

Sponsors (3)

Lead Sponsor	Collaborator
CD Pharma India Pvt. Ltd.	All India Institute of Medical Sciences, New Delhi, Indian Council of Medical Research

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To compare the effect of probiotics and lactulose based on normalization of the abnormal test parameters, Neuropsychometric tests, P3ERP, EEG, venous ammonia levels, Development of overt encephalopathy and other complications and HRQOL		2 months	No